BotableBook a call
FDA Warning Letter Explorer
Drugs · Apr 7, 2026

Lexia LLC

8 extracted findings

FDA source excerpt, selected passage

Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release. Your firm also failed to conduct appropriate laboratory testing, as necessary, for each batch of drug product required to be free of objectionable microorganisms (21 CFR 211.165(a) and 211.165(b)).

Findings and supporting evidence

Model-assisted readings, not an exhaustive interpretation. Compare with the extracted source findings below.

Findings extracted from the letter

Selected FDA passages, not the complete letter.

01
Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release. Your firm also failed to conduct appropriate laboratory testing, as necessary, for each batch of drug product required to be free of objectionable microorganisms (21 CFR 211.165(a) and 211.165(b)).
02
Your firm failed to conduct adequate finished product release testing for each batch of your drug products including, but not limited to, testing the identity and strength of the active ingredient, **(b)(4)**, and testing for objectionable microorganisms.
03
Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).
04
Your firm failed to test incoming components used in manufacturing your finished OTC drug products to determine identity, purity, strength, and quality. Additionally, your firm did not establish a vendor qualification program for your raw material suppliers.
05
Your firm failed to assure that the drug product bore an expiration date that was supported by appropriate stability testing (21 CFR 211.137(a)).
06
Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).
07
Your firm failed to establish an adequate quality unit and the responsibilities and procedures applicable to the quality control unit are not in writing and fully followed (21 CFR 211.22(a) and (d).
08
Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.

Sections and clauses cited

As cited in this historical letter, not a statement of current regulatory requirements.

21 CFR 21021 CFR 211.165(a)21 CFR 211.84(d)(1)21 CFR 211.84(a)21 CFR 211.137(a)21 CFR 211.100(a)21 CFR 211.22(a)21 CFR 211.19221 CFR 211.180(e)21 CFR 211.170(b)21 CFR 211.198(a)21 CFR 211.150(b)21 CFR 211.188(b)21 CFR 211.67(b)21 CFR 211.25(a)

For background, see Complaints. Explore Botable’s work in Pharmaceuticals and Quality and regulatory operations.

Keep exploring

Find related letters →Browse your letters
For regulated teams

Put this kind of reading to
work on your own records.

Botable builds and runs a custom AI layer around the software you already use, so your team can do the job you hired them for.

Book a call ↗Read the case studies

FDA Warning Letter Alerts

Share this view

Send the same filters, search and view to a colleague.

LinkedIn Email

You choose what to post or send. Sharing a link does not change access to this site.